Literature DB >> 12463468

Side effects of anti-TNF therapy: current knowledge.

C Antoni1, J Braun.   

Abstract

The development of the anti-TNF therapies is a milestone in the therapy of rheumatic diseases. As in all new treatment opportunities it is of concern whether all potential undesired side effects have been evaluated within the clinical trials which have lead to approval of the drugs. Postmarketing experience and pharmacovigilance programs are necessary to determine the overall safety profile of the new agents. From the clinical trials and the practical experience of the first years we know that side effects have occurred in patients treated with anti-TNF agents. Sufficient knowledge about these partly specific side effects is critical for rheumatologists who treat their patients with these very effective biologic drugs.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12463468

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  50 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

Review 3.  [Biologicals: a new therapeutic approach for inflammatory diseases].

Authors:  C E Antoni; B Manger
Journal:  Internist (Berl)       Date:  2004-06       Impact factor: 0.743

4.  Pharmacokinetics and safety of intravitreally delivered etanercept.

Authors:  Sascha Fauser; Hubert Kalbacher; Nils Alteheld; Kan Koizumi; Tim U Krohne; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-17       Impact factor: 3.117

Review 5.  Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?

Authors:  Zili Zhang; James T Rosenbaum; Wenwei Zhong; Carmen Lim; David J Hinrichs
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

6.  Production and Purification of a Novel Anti-TNF-α Single Chain Fragment Variable Antibody.

Authors:  Ali Akbar Alizadeh; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2015-12-31

Review 7.  Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.

Authors:  Silja Rott; Ulrich Mrowietz
Journal:  BMJ       Date:  2005-03-26

Review 8.  The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?

Authors:  Muki S Shey; Nigel J Garrett; Lyle R McKinnon; Jo-Ann S Passmore
Journal:  Innate Immun       Date:  2013-11-26       Impact factor: 2.680

9.  Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Toktas; E Okur; U Dundar; A Dikici; O K Kahveci
Journal:  Clin Rheumatol       Date:  2014-04-27       Impact factor: 2.980

10.  Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.

Authors:  Kenan Aksu; Seckin Cagirgan; Nazan Ozsan; Gokhan Keser; Fahri Sahin
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.